17 May 2018 - Deborah Wilkes
Archived
Successful switches of medicines from prescription-to-OTC status have three things in common, according to Mark Bowden, vice-president global regulatory affairs at Pfizer Consumer Healthcare. “The right product is joined up with the right set of company capabilities and commitment at a time when the market is truly ready for it,” he says describing this as the “switch sweet spot”.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.